Ruffer LLP Has $2.04 Million Stock Position in Exelixis, Inc. $EXEL

Ruffer LLP decreased its position in Exelixis, Inc. (NASDAQ:EXEL) by 43.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,500 shares of the biotechnology company’s stock after selling 35,196 shares during the period. Ruffer LLP’s holdings in Exelixis were worth $2,041,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after acquiring an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after acquiring an additional 68,133 shares in the last quarter. Focus Partners Wealth raised its holdings in Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after acquiring an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its holdings in Exelixis by 23.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after acquiring an additional 2,764 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling

In other news, Director Bob Oliver sold 30,250 shares of Exelixis stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.81, for a total value of $1,325,252.50. Following the completion of the transaction, the director owned 21,120 shares in the company, valued at approximately $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jack L. Wyszomierski sold 99,574 shares of Exelixis stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the completion of the transaction, the director owned 279,942 shares of the company’s stock, valued at $12,320,247.42. This trade represents a 26.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 362,849 shares of company stock valued at $15,917,463 in the last ninety days. 2.82% of the stock is owned by corporate insiders.

Exelixis Stock Up 2.1%

Shares of EXEL opened at $46.85 on Thursday. The stock has a market cap of $11.90 billion, a price-to-earnings ratio of 16.91, a P/E/G ratio of 1.03 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $49.62. The company has a 50-day moving average price of $43.18 and a two-hundred day moving average price of $42.55.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. Equities research analysts expect that Exelixis, Inc. will post 3.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on EXEL. Wells Fargo & Company upped their price target on Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. Barclays raised their price target on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Monday. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Royal Bank Of Canada cut their price target on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a research note on Monday, March 2nd. Finally, UBS Group set a $41.00 price target on shares of Exelixis in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $47.00.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.